drugset / Trial / NCT00865943
A Relative Bioavailability Study of Citalopram HBr 10 mg Tablets Under Fasting Conditions
RandomizedCrossoverOpen-label
Summary
The purpose of this study is compare the relative bioavailability of 10 mg Citalopram Hydrobromide tablets by Purepac Pharmaceutical Co with that of 10 mg CELEXATM tablets distributed and marketed by Forest Pharmaceuticals, Inc. following a single oral dose (1 x 10 mg tablet) in healthy adult volunteers under fasting conditions
Timeline
- Start
- 2003-07
- Primary completion
- 2003-08
- Completion
- 2003-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Citalopram | Small molecule | 10 mg | Oral |
Indications
No indication recorded.